Pacific Biosciences of California, Inc. filings document operating results, governance changes, material agreements, and asset-disposition activity tied to its sequencing business. Recent Form 8-K reports furnish quarterly and full-year financial results, business updates, revenue categories for instruments, consumables, and services, and disclosures related to the company’s long-read sequencing focus.
The filing record also includes proxy materials covering board structure, director elections, executive compensation, equity awards, and stockholder voting matters. Other 8-K disclosures address board appointments, changes in accounting-officer responsibilities, operating responsibility assignments, intellectual-property arrangements, and the completed sale of assets related to short-read DNA sequencing technology.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Christopher Gibson received a grant of stock options covering 74,497 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036. They vest monthly over one year, so long as he continues serving as a director through each vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA director Christopher M. Smith received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share, expire on June 3, 2036, and vest monthly over one year while he continues serving as a director. Following this grant, he holds options on 223,492 shares directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Hannah Valantine received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036.
The options will vest monthly over one year, or earlier on the date of the next annual meeting of the company’s stockholders after the grant date, as long as she continues serving as a director. Following this grant, she holds 223,492 derivative securities directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported a new stock option grant for director Randall S. Livingston. He received options covering 223,492 shares of common stock at an exercise price of $1.58 per share. The options vest monthly over one year or earlier upon the next annual stockholder meeting, as long as he continues serving as a director, and expire on June 3, 2036. This filing reflects a compensation-related award, with no open-market share purchases or sales.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director William W. Ericson received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share and expire on June 3, 2036. According to the grant terms, these options vest monthly over one year, or earlier on the date of the next annual stockholder meeting, provided he continues to serve as a director through each vesting date. After this award, the filing shows 223,492 option shares held directly.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director John F. Milligan reported a grant of 223,492 stock options. The options have an exercise price of $1.58 per share, vest monthly over one year or earlier at the next annual stockholder meeting, and expire on June 3, 2036.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. director Kathy Ordonez received a grant of stock options covering 223,492 shares of common stock. The options have an exercise price of $1.58 per share, were granted at no cost, and expire on June 3, 2036.
These options vest monthly over one year, or earlier on the date of the next annual meeting of stockholders after the grant date, as long as she continues to serve as a director through each vesting date. Following this grant, her reported stock option holdings from this award total 223,492 shares.
Pacific Biosciences of California, Inc. reported results of its annual stockholder meeting and approval of an equity plan change. Stockholders approved an amendment to the 2020 Equity Incentive Plan, adding 16,000,000 shares of common stock reserved for future equity awards, following prior Board approval.
At the June 3, 2026 meeting, holders of 203,009,375 shares, about 65% of the 310,487,099 shares outstanding as of April 6, 2026, were represented. Stockholders elected Class III directors, ratified Ernst & Young LLP as auditor for 2026, approved named executive officer compensation on an advisory basis, and confirmed the equity plan amendment.
Pacific Biosciences of California, Inc. reported Q1 2026 revenue of $37.2 million, essentially flat year over year, with higher consumable sales offsetting softer instrument and service revenue. Revio system placements rose while Vega unit volumes and pricing were pressured by promotions and funding constraints.
Gross profit improved to $12.8 million from a gross loss of $1.4 million a year earlier as cost of revenue declined sharply. The company posted a much smaller net loss of $8.3 million versus $426.1 million in Q1 2025, largely because the prior period included large one-time amortization and impairment charges and the current quarter benefited from a $45.8 million gain on an asset sale to Illumina.
Cash, cash equivalents and investments totaled $276.0 million as of March 31, 2026, only slightly below year-end. PacBio highlights continued restructuring-driven operating expense reductions, a new license and settlement agreement with PGI that creates fixed payments through 2029, and an ongoing focus on driving HiFi sequencing adoption via the Revio and Vega platforms and upcoming SPRQ-Nx consumables.
Pacific Biosciences of California, Inc. reported first quarter 2026 revenue of $37.2 million, flat year over year, with stronger consumables offset by weaker instrument sales. Consumable revenue rose to $21.8 million from $20.1 million, while instrument revenue declined to $9.7 million from $11.0 million.
GAAP gross margin improved to 35% from negative 4% a year ago, and GAAP net loss narrowed sharply to $8.3 million from $426.1 million, helped by restructuring actions and a gain on disposing short-read sequencing assets. Non-GAAP net loss improved to $35.9 million from $44.4 million.
The company completed the sale of short-read assets for net cash proceeds of about $48.1 million, ending the quarter with $276.0 million in cash, cash equivalents, and investments. Management expects full-year 2026 revenue between $165 million and $175 million, supported by growing clinical adoption of HiFi sequencing and an expanded SPRQ-Nx rollout.